Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

October 21, 2027

Study Completion Date

December 1, 2027

Conditions

Prostate Cancer

Interventions

RADIATION

Radiotherapy

DRUG

Leuprorelin

Hormonal therapy

Trial Locations (13)

Radiotherapiegroep, Arnhem

Radboud University Medical Center, Nijmegen

Maastro Clinic, Maastricht

Catharina Hospital, Eindhoven

Amsterdam UMC (Location VUmc), Amsterdam

Radiotherapiegroep, Deventer

Isala, Zwolle

Radiotherapy Institute Friesland, Leeuwarden

Leinden University Medical Center, Leiden

Erasmus Medical Center, Rotterdam

Haga Hospital, The Hague

UMCG, Groningen

Verbeeten Institute, Tilburg

All Listed Sponsors

collaborator

Dutch Cancer Society

OTHER

lead

University Medical Center Groningen

OTHER

NCT04302454 - Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy | Biotech Hunter | Biotech Hunter